ArticleVaccines2026

Safety and Immunogenicity of the Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults: Results from a Phase 2, Randomized, Controlled, Dose-Finding Trial with Long-Term Extension Follow-Up Through Month 48.

Carlos Fierro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.